Clinical Trial Results:
A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin in Treatment-Experienced Subjects with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL–II)
Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines.
Summary
|
|
EudraCT number |
2011-005740-95 |
Trial protocol |
SE AT BE NL IT PT |
Global end of trial date |
13 Oct 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 May 2016
|
First version publication date |
18 May 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
M13-389
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01674725 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
AbbVie Deutschland GmbH & Co. KG
|
||
Sponsor organisation address |
Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United Kingdom, SL6 4XE
|
||
Public contact |
Global Medical Information, AbbVie, 001 800-633-9110,
|
||
Scientific contact |
Jeffrey Enejosa, MD, AbbVie, jeffrey.enejosa@abbvie.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
13 Oct 2014
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
13 Oct 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The purpose of this study is to evaluate the safety and antiviral activity of ABT-450/ritonavir/ABT- 267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) with and without ribavirin (RBV) in patients with chronic hepatitis C virus genotype 1b (HCV GT1b) infection without cirrhosis.
|
||
Protection of trial subjects |
Subject read and understood the information provided about the study and gave written permission.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
14 Aug 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Switzerland: 13
|
||
Country: Number of subjects enrolled |
Turkey: 30
|
||
Country: Number of subjects enrolled |
United States: 33
|
||
Country: Number of subjects enrolled |
Netherlands: 5
|
||
Country: Number of subjects enrolled |
Portugal: 4
|
||
Country: Number of subjects enrolled |
Sweden: 11
|
||
Country: Number of subjects enrolled |
Austria: 22
|
||
Country: Number of subjects enrolled |
Belgium: 24
|
||
Country: Number of subjects enrolled |
Italy: 45
|
||
Worldwide total number of subjects |
187
|
||
EEA total number of subjects |
111
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
156
|
||
From 65 to 84 years |
31
|
||
85 years and over |
0
|
|
||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||
Recruitment details |
- | |||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||
Screening details |
A total of 187 subjects were randomized; 1 subject did not receive study drug and was excluded from the analyses. | |||||||||||||||||||||
Period 1
|
||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
|||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Not blinded | |||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
ABT-450/r/ABT-267 and ABT-333, Plus RBV | |||||||||||||||||||||
Arm description |
ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
ABT-450/r/ABT-267
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, Viekirax
|
|||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||
Dosage and administration details |
ABT-450 (150 mg) coformulated with ritonavir (100 mg) and ABT-267 (25 mg)
|
|||||||||||||||||||||
Investigational medicinal product name |
ABT-333
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
dasabuvir, Exviera
|
|||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||
Dosage and administration details |
250 mg twice daily
|
|||||||||||||||||||||
Investigational medicinal product name |
Ribavirin
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||
Dosage and administration details |
Weight-based (dosed 1,000 or 1,200 mg daily divided twice a day)
|
|||||||||||||||||||||
Arm title
|
ABT-450/r/ABT-267 and ABT-333 | |||||||||||||||||||||
Arm description |
ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
ABT-450/r/ABT-267
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, Viekirax
|
|||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||
Dosage and administration details |
ABT-450 (150 mg) coformulated with ritonavir (100 mg) and ABT-267 (25 mg)
|
|||||||||||||||||||||
Investigational medicinal product name |
ABT-333
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
dasabuvir, Exviera
|
|||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||
Dosage and administration details |
250 mg twice daily
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Notes [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: A total of 187 subjects were randomized; 1 subject did not receive study drug and was excluded from the intent-to-treat (ITT) and safety populations. |
|
|||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
ABT-450/r/ABT-267 and ABT-333, Plus RBV
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks | ||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
ABT-450/r/ABT-267 and ABT-333
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks | ||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
ABT-450/r/ABT-267 and ABT-333, Plus RBV
|
||
Reporting group description |
ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks | ||
Reporting group title |
ABT-450/r/ABT-267 and ABT-333
|
||
Reporting group description |
ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks |
|
|||||||||||||
End point title |
Percentage of Subjects With Sustained Virologic Response 12 Weeks After Treatment; Primary Analyses [1] | ||||||||||||
End point description |
The percentage of subjects with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL. Subjects with missing data were counted as non-responders.
The primary endpoints were noninferiority of the percentage of subjects who achieved sustained virologic response 12 weeks after treatment in each treatment arm compared with the historical control rate for noncirrhotic, treatment-experienced subjects with HCV GT1b infection treated with telaprevir and peginterferon (pegIFN)/RBV. Based on a 2-sided significance level of 0.05 and underlying rates of ≥90% (n=90 in each arm), a total of 180 subjects provides >90% power to demonstrate noninferiority of each regimen to the historical rate (75%) (based on the normal approximation of a single binomial proportion in a one-sample test for superiority).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
12 weeks after last dose of study drug
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The lower confidence bound of the 2-sided 95% confidence interval for the percentage of subjects with sustained virologic response at 12 weeks after treatment must exceed 64% to achieve noninferiority. 95% CI was calculated using the normal approximation to the binomial distribution (ABT-450/r/ABT-267 and ABT-333) or the Wilson score method for the single proportion because the point estimate was 100% (ABT-450/r/ABT-267 and ABT-333, plus RBV). |
|||||||||||||
|
|||||||||||||
Notes [2] - ITT GT1b population: All subjects with HCV GT1b infection who received at least 1 dose of study drug [3] - ITT GT1b population: All subjects with HCV GT1b infection who received at least 1 dose of study drug |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment | ||||||||||||
End point description |
The percentage of subjects with a decrease in hemoglobin from greater than or equal to the lower limit of normal (≥ LLN) at baseline to < LLN at the end of treatment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Day 1) and Week 12 (End of Treatment)
|
||||||||||||
|
|||||||||||||
Notes [4] - Subjects in the ITT HCV GT1b population with hemoglobin ≥ LLN reference range at baseline [5] - Subjects in the ITT HCV GT1b population with hemoglobin ≥ LLN reference range at baseline |
|||||||||||||
Statistical analysis title |
Statistical Analysis 1 | ||||||||||||
Comparison groups |
ABT-450/r/ABT-267 and ABT-333, Plus RBV v ABT-450/r/ABT-267 and ABT-333
|
||||||||||||
Number of subjects included in analysis |
179
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
Fisher exact | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Percentage of Subjects With Sustained Virologic Response 12 Weeks After Treatment; Secondary Analyses | ||||||||||||
End point description |
The percentage of subjects with sustained virologic response (plasma HCV RNA less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. Subjects with missing data were counted as non-responders.
The secondary endpoints were superiority of the percentage of subjects who achieved sustained virologic response 12 weeks after treatment in each treatment arm compared with the historical control rate for noncirrhotic, treatment-experienced subjects with HCV GT1b infection treated with telaprevir and pegIFN/RBV (75%) (the lower confidence bound must exceed 75% to achieve superiority); and noninferiority of the percentage of subjects who achieved sustained virologic response 12 weeks after treatment with ABT-450/r/ABT-267 and ABT-333, plus RBV compared with ABT-450/r/ABT-267 and ABT-333 (see statistical analysis 1).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
12 weeks after last dose of study drug
|
||||||||||||
|
|||||||||||||
Notes [6] - ITT GT1b population [7] - ITT GT1b population |
|||||||||||||
Statistical analysis title |
Statistical Analysis 1 | ||||||||||||
Statistical analysis description |
95% CI was calculated using the normal approximation to the binomial distribution.
|
||||||||||||
Comparison groups |
ABT-450/r/ABT-267 and ABT-333, Plus RBV v ABT-450/r/ABT-267 and ABT-333
|
||||||||||||
Number of subjects included in analysis |
179
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
non-inferiority [8] | ||||||||||||
Method |
|||||||||||||
Parameter type |
Percentage of subjects | ||||||||||||
Point estimate |
2.3
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.8 | ||||||||||||
upper limit |
5.4 | ||||||||||||
Notes [8] - The noninferiority of the rate of sustained virologic response at 12 weeks after treatment for the ABT-450/r/ABT-267 and ABT-333 treatment group as compared with the ABT-450/r/ABT-267 and ABT-333, plus RBV treatment group was analyzed using a noninferiority margin of -10.5%; the lower confidence bound of the 2-sided 95% confidence interval for the difference in percentage of subjects with sustained virologic response at 12 weeks after treatment must exceed -10.5% to achieve noninferiority. |
|
|||||||||||||||||||
End point title |
Percentage of Subjects With Virologic Failure During Treatment | ||||||||||||||||||
End point description |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log10 IU/mL above the lowest value post baseline] at any time point during treatment), or failure to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment).
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, and 12
|
||||||||||||||||||
|
|||||||||||||||||||
Notes [9] - ITT GT1b population [10] - ITT GT1b population |
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With Virologic Relapse After Treatment | ||||||||||||
End point description |
Subjects who completed treatment with plasma HCV RNA less than the lower limit of quantification (<LLOQ) at the end of treatment were considered to have virologic relapse if they had confirmed HCV RNA ≥ LLOQ during the post-treatment period. 95% CI was calculated using the Wilson score method for the single proportion because the point estimate was 0%.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Between End of Treatment (Week 12) and Post-treatment (up to Week 12 Post-Treatment)
|
||||||||||||
|
|||||||||||||
Notes [11] - ITT GT1b population with HCV RNA < LLOQ at the final treatment visit and completed treatment [12] - ITT GT1b population with HCV RNA < LLOQ at the final treatment visit and completed treatment |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
AEs were collected from the time of study drug administration to 30 days after last dose of study drug (16 weeks); SAEs were also collected from the time that informed consent was obtained until the end of participation in the study (up to 64 weeks)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
16.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
ABT-450/r/ABT-267 and ABT-333, Plus RBV
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
ABT-450/r/ABT-267 and ABT-333
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
08 Feb 2012 |
The purpose of this amendment was to clarify when Arms 3 and 4 were opened for enrollment; remove RBV from list of previous anti-HCV agents prohibited in exclusion criteria; correct time frame for qualifying biopsy from 3 years to 24 months; remove requirement for consenting pregnant partners. |
||
17 Feb 2012 |
The purpose of this amendment was to clarify that subjects may not have used other anti-HCV agents with exception of pegIFN/RBV combination therapy. |
||
25 May 2012 |
The purpose of this amendment was to remove the 8-week arms (Arms 3 and 4); replace extended virologic response (eRVR) with end of treatment response (EOTR) as a secondary endpoint; revise treatment futility criteria; update options for treatment for subjects currently undergoing treatment in a study arm or subgenotype that was terminated due to futility criteria being met and allow for use of pegIFN and RBV as an add-on therapy; modify definitions for null responders and nonresponder/partial responders; clarify conditions under which a subject may have been allowed to re-screen; clarify contraception requirements; clarify screening requirements (FibroTest or FibroScan, liver diagnostic testing, HCV genotype 1 result, platelet results, discontinuation of pegIFN/RBV within 2 months of the screening visit); and clarify recording of medications. |
||
24 Sep 2012 |
The purpose of this amendment was to stop further enrollment of HCV GT1a-infected subjects and only allow HCV GT1b-infected subjects to be enrolled, and provide options for the HCV GT1a-infected subjects who were currently enrolled; removing HCV subgenotype from primary and secondary analyses and update screening and inclusion/exclusion criteria. |
||
28 Nov 2012 |
The purpose of this amendment was to modify the protocol to a Phase 3 study; increase sample size of the study and change randomization for 1:1 for all pegIFN/RBV treatment experienced populations (null responders, nonresponders/partial responders, and relapsers); change the investigational product supply to use the combination ABT-450/r/ABT-267 tablet and to adjust the dose and strength of the ABT-333 tablet; and change the primary and secondary endpoints to compare SVR12 rate of each arm with the historical SVR rate of telaprevir plus pegIFN/RBV. |
||
29 Jan 2013 |
The purpose of this amendment was to update the definition of relapsers to expand the timeframe for testing from 24 weeks to 52 weeks to allow subjects that may have detectable viral load documentation more than 24 weeks after treatment; update to allow testing of the genotype/subgenotype if not known prior to completing all the screening procedures; update inclusion criteria (include that depo-progesterone may not be an effective form of contraception for a female subject, depo-progesterone may be an effective form of contraception for female partners of male subjects in the trial); update exclusion criteria (provide guidance for female subjects with borderline human chorionic gonadotropin (hCG) test results; add a contraindicated medication; provide guidance to address subjects with steatosis and steatohepatitis; update absolute neutrophil count (ANC) and international normalized ratio (INR); update conditions for discontinuation and follow-up of subects who become pregnant; add a data monitoring committee DMC). |
||
08 Apr 2013 |
The purpose of this amendment was to prohibit the use of hormonal contraceptives during study drug administration. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |